Sonoma Pharmaceuticals (SNOA) Capital Expenditures Growth (5y) (2015 - 2026)
Sonoma Pharmaceuticals (SNOA) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Sonoma Pharmaceuticals | 1.92 Mn | -479,240.02 | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.13% |
| Dec 31, 2025 | -9.40% |
| Sep 30, 2025 | -25.98% |
| Jun 30, 2025 | 15.31% |
| Mar 31, 2025 | -39.71% |
| Dec 31, 2024 | 15.05% |
| Sep 30, 2024 | 15.96% |
| Jun 30, 2024 | -16.06% |
| Mar 31, 2024 | -26.86% |
| Dec 31, 2023 | -49.01% |
| Sep 30, 2023 | -41.82% |
| Jun 30, 2023 | -8.84% |
| Mar 31, 2023 | 84.04% |
| Dec 31, 2022 | 14.14% |
| Sep 30, 2022 | 37.97% |
| Jun 30, 2022 | -31.90% |
| Mar 31, 2022 | -20.80% |
| Dec 31, 2021 | -62.28% |
| Sep 30, 2021 | -12.94% |
| Jun 30, 2021 | 28.47% |